

# IMI: SPANISH VISION

Marta Gómez Quintanilla  
IMI Spanish Representative

VII PM/H2020

marta.gomez[at]cdti.es

<http://bit.ly/1ghtQJm>

22 de junio de 2015

# Index

- **Participation**
- **IMI in context**
- **Support measures**

# Participation

Participate in

- projects / proposals
- European initiatives



Lobbying




Expert



# Participant Portal

<http://ec.europa.eu/research/participants/portal/desktop/en/home.html>




## RESEARCH & INNOVATION

### Participant Portal

European Commission > Research & Innovation > Participant Portal > Home

[HOME](#) [FUNDING OPPORTUNITIES](#) [HOW TO PARTICIPATE](#) [EXPERTS](#) [SUPPORT ▾](#)

[LOGIN](#) [REGISTER](#)



## Horizon 2020 Funding

Starting from 1/1/2014

On this site you can find and secure **funding** for research & innovation projects under the following EU programmes:


- **2014-2020** Horizon 2020 - research and innovation framework programme
- **2007-2013** 7th research framework programme (FP7) and Competitiveness & Innovation Programme (CIP)

#### Non-registered users


- search for funding
- read the funding guide & download the legal documents
- check if an organisation is already registered
- contact our support services or check our FAQs

#### Registered users


- submit your proposal
- sign the grant
- manage your project throughout its lifecycle




WHAT'S NEW?




FUNDING OPPORTUNITIES




HOW TO PARTICIPATE



WORK AS AN EXPERT



MY PERSONAL AREA



INFORMATION AND SUPPORT

# Experts


<http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html>



## Important to remember !

- Experts should **regularly update their profile to ensure that the European Commission can find the best match of assignments in the future.**

**Pay particular attention to the new list of keywords defining specialist themes!!**



PERSONAL details LANGUAGES EDUCATION **AREA of expertise** PROFESSIONAL experience DATA privacy

Welcome e ramos  
Identification number: EX20026004127  
Status: Invalid

Personal Details Languages Education Area of Expertise Professional Experience Data Privacy

Questions? FAQ contact

### Area of Expertise

Please tell us about your field of expertise using the interactive navigation trees provided and finally in your own words.

A Specialist Field(s) B Pre-defined Themes C Open Keywords

#### My pre-defined themes

Let us know which pre-defined themes best describe your expertise. Please select **at least 2**.

The pre-defined list presents the thematic domains for European Union under its research programme.

1. Energy->Smart energy networks
2. Energy->Energy efficiency and savings
3. Information and Communication Technologies->Integration of Technologies
4. Energy->Renewable electricity generation

#### SEARCH EXPERTS

To search the database of experts, use at least one of the following categories to identify the specific criteria of interest. Detailed sub-criteria are available under 'Advanced search'.

##### Expertise

###### Specialist fields

Select Specialist fields (press Ctrl+Shift to select multiple fields):

- Applied mathematics
- Applied optics
- Applied psychology**

###### Predefined themes

Select themes (press Ctrl+Shift to select multiple themes):

- Smart energy networks**
- Societal trends and lifestyles
- Socio-economic and scientific indicators
- Socio-economic issues

# Participation

Participate in

- projects / proposals
- European initiatives



Lobbying



Expert





# Governance

[www.imi.europa.eu/content/governance](http://www.imi.europa.eu/content/governance)





# Composición GB y SC

## Members of the IMI2 Governing Board

Update  
2 March 2015

1.	<b>Marc de Garidel</b>	Chief Executive Officer of Ipsen Group, member of the EFPIA Board and Vice-President of EFPIA	EFPIA / Ipsen
2.	<b>Richard Bergström</b>	Director General of EFPIA	EFPIA
3.	<b>Salah-Dine Chibout</b>	Global Head Discovery and Investigational Safety at Novartis, Chairman of the EFPIA Research Directors Group	EFPIA / Novartis
4.	<b>Carlo Incerti</b>	Head of Global Medical Affairs at Genzyme, member of the EFPIA Board, member of the EFPIA Research Directors Group (ex-officio EBE)	EFPIA / Genzyme
5.	<i>vacancy</i>	To be filled in Q1 2015	EFPIA
6.	<b>Rudolf Strohmeier</b>	Deputy Director-General responsible for research programmes within the Directorate-General for Research and Innovation	European Commission
7.	<b>Ruxandra Draghia-Akli</b>	Director responsible for health within the Directorate-General for Research and Innovation	European Commission
8.	<b>Arnd Hoeveler</b>	Head of unit responsible for novel medical developments within the Directorate-General for Research and Innovation	European Commission
9.	<b>Gwenole Cozigou</b>	Director responsible for resources based, manufacturing and consumer goods industries within the Directorate-General for Internal Market, Industry, Entrepreneurship	European Commission
10.	<b>Andrzej Jan Rys</b>	Director responsible for health systems and products within the Directorate-General for Health and Food Safety	European Commission

Mr Rudolf Strohmeier was elected as Deputy Chairperson on the meeting of 7 July 2014.  
Mr Marc de Garidel, C.E.O. of the Ipsen pharmaceutical company was elected as Chairperson of the IMI2 Governing Board on the meeting of 2 March 2015, replacing Mr Roch Doliveux for the remaining term of office, until 6 July 2015.

## Members of the IMI2 Scientific Committee

**Johan Askling** (ad hoc)

Professor of Rheumatology and Rheumatic Disease Epidemiology, Dept of Medicine Solna, Karolinska Institutet, Stockholm, SWEDEN

**Janusz Bujnicki** (member)

Professor of Biological Sciences, International Institute of Molecular and Cell Biology, Warsaw, POLAND

**Maria Beatriz Da Silva Lima** (Chair)

Professor of Pharmacology and Pharmacotoxicology, Lisbon University, Lisbon, PORTUGAL

Hans-Georg Eichler (ad hoc)

Senior Medical Officer, European Medicines Agency, London, UK

**Karin Forsberg-Nilsson** (member)

Professor of Stem Cell Research, Uppsala University, Uppsala, SWEDEN

**Jens Heisterberg** (member)

Chief Medical Officer, Danish Medicines Agency, Copenhagen, DENMARK

**Pierre Laurent-Puig** (member)

Professor of Oncology at the Paris Descartes Medical School, Paris, FRANCE

**Carole Longson** (member)

Executive Director, National Institute for Health and Clinical Excellence (NICE), London, UNITED KINGDOM

**Françoise Meunier** (member)

Director General, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, BELGIUM

**Maria Navarro** (member)

President of the Spanish Patients' Forum, Director of the Global Institute of Public Health, Universitat Internacional de Catalunya, SPAIN

**Markus Perola** (Vice-Chair)

Research Professor in the Institute for Health and Welfare, University of Helsinki, FINLAND

**Daniele Piomelli** (ad hoc)

Director, Drug Discovery and Development (D3) Research Unit, Istituto Italiano di Tecnologia (IIT), Genoa, ITALY; Director, Centre for Drug Discovery, University of California Irvine (UCI), US

**Torsten Schwede** (member)

Professor for Bioinformatics, Biozentrum, University of Basel, Basel, SWITZERLAND


**Leonie Sundmacher** (member)

Professor for Health Services Management, Ludwig Maximilians University, Munich, GERMANY

# Composición SRG


The position of Chair is held by Marta Gómez Quintanilla (Spain) and the position of Vice-Chair by Gunnar Sandberg (Sweden).

The Chair and the Vice-Chair are elected for a period of two years.

More information about the SRG is available in the [Rules of Procedure of the IMI2 JU States Representatives Group](#) 

- |  |  |  |  |
|--|--|--|--|
| ▪  AUSTRIA        | ▪  GERMANY      | ▪  NETHERLANDS      | ▪  BOSNIA-HERZEGOVINA |
| ▪  BELGIUM        | ▪  GREECE       | ▪  POLAND           | ▪  ICELAND            |
| ▪  BULGARIA       | ▪  HUNGARY      | ▪  PORTUGAL         | ▪  ISRAEL             |
| ▪  CROATIA        | ▪  IRELAND      | ▪  ROMANIA          | ▪  MOLDOVA            |
| ▪  CYPRUS         | ▪  ITALY        | ▪  SLOVAKIA         | ▪  NORWAY             |
| ▪  CZECH REPUBLIC | ▪  LATVIA       | ▪  SLOVENIA         | ▪  TURKEY             |
| ▪  DENMARK       | ▪  LITHUANIA   | ▪  SPAIN           | ▪  UKRAINE           |
| ▪  ESTONIA      | ▪  LUXEMBOURG | ▪  SWEDEN         |  |
| ▪  FINLAND      | ▪  MALTA      | ▪  UNITED KINGDOM |  |
| ▪  FRANCE       |  |  |  |

# Programme Office IMI



## IMI Programme Office Organisation Chart

# IMI's new Executive Director, Pierre Meulien

[www.imi.europa.eu/content/pierre-meulien-new-imi-executive-director](http://www.imi.europa.eu/content/pierre-meulien-new-imi-executive-director)

- Pierre Meulien brings to the post extensive experience of working in academia, industry, and research-funding organisations on both sides of the Atlantic.
- Dr. Meulien comes to IMI from Genome Canada and will take up his duties in mid-September 2015.



# Strategic Governing Groups (SGG) – Role

Make the process of topic development and gathering industry commitment more **transparent, effective and strategic**.

- Advise the Board on
  - Scientific portfolio strategy, Scientific priorities and Annual work plan for selected disease or/and thematic areas,
  - Research projects and programmes, as well as the type of call process that is most suitable and effective,
  - Outreach to/consultation with the scientific, patients, etc. communities;
- As well as
  - Evaluate programmes and projects in light of evolving science and environment as well as on the basis on key milestones,
  - Formulate recommendations to expand or end activities,
  - Seek synergies and complementarities with other similar European and global initiatives.



# SGG: Industrial composition

## Immunology

Lead: GSK

AbbVie,  
Almirall,  
Amgen,  
Astellas, AZ,  
Bayer, Biogen  
Idex,  
Boehringer  
Ingelheim,  
GSK, Janssen,  
Merck, MSD,  
Novartis, Novo  
Nordisk, Pfizer,  
Roche, Sanofi  
Pasteur,  
Takeda, UCB,  
Vifor Pharma

## Diabetes & Metabolic Disorders

Lead: Sanofi,  
co-lead: Eli Lilly,  
Servier

Amgen, AZ,  
Boehringer  
Ingelheim, Eli  
Lilly, GSK,  
Janssen, MSD,  
Novartis, Novo  
Nordisk, Pfizer,  
Sanofi, Servier

## Neuro-degeneration

Lead: Janssen,  
colead: Eli Lilly,  
Abbvie

AbbVie, AZ,  
Biogen Idec,  
Boehringer  
Ingelheim,  
EISAI, Eli Lilly,  
GSK,  
Grünenthal,  
Ipsen, Janssen,  
Lundbeck,  
Merck, MSD,  
Novartis, Orion,  
Pfizer, Roche,  
Sanofi, Servier,  
UCB

## Translational safety

Lead: Sanofi,  
co-leads: Bayer,  
Janssen,  
Novartis

AbbVie, AZ,  
Bayer,  
Boehringer  
Ingelheim, Eli  
Lilly, GSK,  
Janssen,  
Merck, Novartis,  
Novo Nordisk,  
Pfizer, Roche,  
Sanofi, Servier,  
UCB, Vifor  
Pharma

## Data & Knowledge Management

Lead: Janssen,  
colead: Pfizer

Astellas, AZ,  
Bayer, Daiichi-  
Sankyo,  
Genzyme, GSK,  
Grünenthal,  
Janssen, MSD,  
Novo Nordisk,  
Pfizer, Roche,  
Sanofi, Servier,  
UCB


## Infections control

Leads:  
AZ/Medimmune

AiCuris,  
Astellas, AZ,  
Basilea, Cubist,  
GSK, J&J,  
Pfizer (tbc),  
Sanofi, Vifor,  
Menarini (tbc),  
MSD, Novartis  
and Roche (tbc)



# SGG – Topic definition process



9

Figure 1: SGGs input into the IMI workflow



# IMI2 – Idea generation for future topics

<http://imi.efpia.eu/imi2/create-your-imi2>

## Create your IMI2

### Innovative Medicines Initiative2: Idea generation and development of Call topics

Strategic Research Agenda (SRA): The right prevention and treatment, to the right patient at the right time

*Who will translate the SRA into projects?*

*Can third parties submit a proposal?*


*Can the proposer be part of the IMI consortium?*

*Is there a template?*

*When to submit an idea?*

*What happens after submission?*

*Need more information?*



# IMI2 –EFPIA Idea generation website

<http://imi.efpia.eu/imi2/imi2-idea-generation>

IMI

Achievements

IMI2

Media Room

Resources

Contact

Search...

## IMI2 idea generation

### ABOUT YOU

#### YOUR PROPOSAL

Scientific question/topic for IMI2\*

Rationale - problem statement \*

Expected deliverables and impact \*

Is it a place to address your scientific question/project?\*

#### RELEVANCE TO THE STRATEGIC RESEARCH AGENDA

Therapeutic areas covered by the SRA

Enablers for each theme

#### RELEVANCE TO IMI2 COLLABORATIVE SCHEME

Why is IMI2 an ideal place to address your scientific question/project?



División  
Programas de la UE

# IMI Stakeholder Forum 2015

[www.imi.europa.eu/events/2015/03/13/imi-stakeholder-forum-2015](http://www.imi.europa.eu/events/2015/03/13/imi-stakeholder-forum-2015)

## IMI Stakeholder Forum 2015

### Agenda

15.06.2015 • Crowne Plaza Le Palace  
Brussels • Belgium

10:30 – 11:00 Registration & welcome coffee

11:00 Welcome

**Rudolph Strohmeier**  
Deputy Director-General responsible for research programmes, Directorate-General for Research and Innovation, European Commission  
Deputy Chair of the IMI Governing Board

11:10 Keynote

11:30 – 13:00 Session 1 | The IMI story: how far have we come?

Chair: Richard Bergström, Director General, EFPIA

Mike Hardman, Vice-President IMI Collaborations, AstraZeneca IMED, IMI EMTRAIN project

Dimitrios Tzalis, CEO, Taros Chemicals, IMI European Lead Factory project

Ferran Sanz, Director, Biomedical Informatics Programme, Universitat Pompeu Fabra, IMI

15:45 – 17:00 Session 3 | Where are we going? The next big things in biomedical R&D

15:45 – 15:50 Introduction by Irene Norstedt

15:50 – 17:00 Parallel tracks

**Session A | Advanced therapies: from treatment to cure & prevention**

**Moderator: Arnd Hoeveler**

Head of unit, novel medical developments, DG Research & Innovation, European Commission

**Rapporteur: Kim Kryger**

IMI States Representatives Group member; Head of section at EuroCenter; National Contact Point for Health and IMI, Programme Committee for Health, Denmark

**Session B | Enabling technologies: better health outcomes through big data**

**Moderator: Stavros Malas**

IMI States Representatives Group member; Group Head, Institute of Neurology and Genetics, Cyprus

*The session serves as a consultation with payers, regulators, prescribers, patients, HTAs as well as all other stakeholders to gather stakeholders' input on an IMI programme proposal for maximising the potential of big data for better outcomes in healthcare. IMI encourages an open debate*

**Session C | Optimising IMI's funding schemes**

**Moderator: Marta Gómez Quintanilla**

Chair of the IMI States Representatives Group, Ministry of Economy and Competitiveness, Spain

**Rapporteur: Elmar Nimmesgern**

Deputy Head of Unit Innovative and Personalised Medicine, Directorate General for Research and Innovation, European Commission

## Big Data for Better Outcomes Session

[www.imi.europa.eu/sites/default/files/uploads/documents/Events/SF%202015/BigData\\_Concept\\_29May2015.pdf](http://www.imi.europa.eu/sites/default/files/uploads/documents/Events/SF%202015/BigData_Concept_29May2015.pdf), que será la base de futuros topics.

Feedback on this concept paper will be sought through:

- A dedicated session during the IMI2 Stakeholder Forum of 15 June 2015
- Written comments and suggestions can also be sent until **25 June 2015** to [health-outcomes@efpia.eu](mailto:health-outcomes@efpia.eu)



# New opportunities in IMI2:

In kind/cash contribution matched by IMI funding for public beneficiaries

IMI

EFPIA full members  
> 1.000 M€

>  
1.000  
M€



> 1.000 M€



IMI2

EFPIA full members  
+ associated partners

>  
1.425  
M€



farmaindustria



Other industries and  
organisations, which can  
contribute to the PPP goals  
(Healthcare IT, medical devices...)

>  
213  
M€

≠

≠

> 1.637 M€



# New opportunities in IMI2:

## Eligibility to receive funding



### IMI

- Academic institutions
- Non-profit organizations
- Small & medium-size enterprises
- Non-profit patient organizations
- Non-profit public bodies
- International European interest organizations



### IMI2

- Academic institutions
- Non-profit organizations
- Small & medium-size enterprises
- **Mid-sized enterprises ( $\leq 500M$ )**
- Non-profit patient organizations
- Non-profit public bodies
- International European interest organizations

≠

# IMI and patients

[www.imi.europa.eu/content/patients](http://www.imi.europa.eu/content/patients)

## IMI and patients - a partnership

Welcome to the new patient page on the IMI website! Here you'll find **news, information and advice** for patients and patient representatives interested in getting involved in IMI, as well as information on how patients are already working in our projects. Over the coming weeks and months we'll be adding more information, stories, and interviews to this section, so **watch this space!**


### News

- Indicative information on future IMI Call topics for 2015 is now available on our **Future Topics** page

### IMI and patients

For many years, patient involvement in research was restricted to participating in clinical studies and trials as research subjects. Today, it is widely recognised that patients can and should be much more involved in all aspects of research, including agenda setting, study design, communication, and ethics. At the same time, researchers are now well aware that patients can help to improve the quality of research. At IMI, there are a number of ways for patients to get involved in our projects and activities. These include:

- as full **project partners**
- as members of **advisory committees**
- by becoming **Associated Partners** of IMI
- by proposing **ideas for topics** to EFPIA

More information on these different options can be found in [this guide](#) 

### Background





Over the years IMI has taken active steps to engage with patients and promote patient involvement in its projects and activities. These include:

- inclusion of a patient representative in the **IMI Scientific Committee** since its creation;
- regular involvement of patients and patient representatives as speakers and panellists in **IMI events**;
- **surveys** revealing patients' interest in contributing to research and awareness of IMI;
- **events** dedicated to patients and patient involvement in IMI;
- active patient involvement in **projects**.

### IMI projects with strong patient involvement include:

- **EUPATI** is developing **training materials and courses** to help patients engage more effectively in medical research and development.
- **U-BIOPRED** is paving the way for more personalised treatments for **severe asthma**. Through a dedicated patient input platform, patients provide advice on ethical, scientific, and communication issues.
- **PROactive** is developing methods to incorporate the impact of **chronic obstructive pulmonary disease (COPD)** on patients' daily lives into drug development.
- Patient organisation **Alzheimer Europe** is an active partner in the IMI projects **Pharma-Cog**, **AETIONOMY**, **EMIF** and **EPAD**.
- **EU-AIMS** is paving the way for new treatments for **autism spectrum disorder**. US-based patient advocacy group **Autism Speaks** is a partner in the project and is contributing €1 million to its work.
- **Diabetes** charity and patient organisation **JDRF** has contributed to IMI's **IMIDIA** and **SUMMIT** projects and is now an **Associated Partner** in IMI 2 as it will contribute resources and expertise to the **IMI 2 – Call 1** project on type 1 diabetes.

### Documents

- **IMI brochure**  - Find out what IMI is, how it works, and find out about some of its main achievements
- **Patient engagement guide**  - Advice to potential applicants from patient groups and other sectors (e.g. academia) for meaningful patient engagement in IMI projects, with a focus on IMI 2 - Calls 3 and 4
- **Report**  - Patient involvement in IMI projects from Calls 1 to 6
- **Report**  - Patients' awareness of IMI and views of patient involvement in research

### Questions?

- Contact us - **infodesk [AT] imi.europa.eu**
- Follow us on Twitter - **@IMI\_JU**

Societal Challenge 1: Health, Demographic Change and Wellbeing



**Tackling Societal  
Challenges**

**Creating Industrial  
Leadership and  
Competitive Frameworks**

**EIT**

**JRC**

**Excellence in the Science Base**


HORIZON 2020



# Opportunities beyond IMI

IMI is part of the Societal Challenge

- **IMI:** Innovative Medicines Initiative
- **AAL:** Active & Assisted Living
- **FET:** Future and Emerging Technologies
- **HBP:** Human Brain Project
- **JPI:** Joint Programming Initiative
- **JPI HD&HL:** A Healthy diet for a healthy life
- **JPND:** Joint Programming in Neurodegenerative Research
- **MYBL:** Joint Programming More Years, Better Lives
- **JPI AMR:** Joint Programming in Antimicrobial Resistance
- **EMPIR:** European Metrology Programme for Innovation and Research
- **EDCTP:** The European and Developing Countries Clinical Trials Partnership
- **KIC HL&AA:** Knowledge and Innovation Communities on Healthy Living and Active Ageing
- **EIP AHA:** European Innovation Partnership on Active and Healthy Ageing





# Partner Search Tools & Data bases - IMI



Contact Newsletter Links

## Welcome to the IMI partner search tool

This is the IMI partner search tool anyone interested in participating in future IMI projects. The tool is meant to help you identify partners for the preparation of an Expression of Interest in response to an IMI Call for proposals. Information on the latest Calls is available [here](#).

Sharing information about your expertise and topic(s) of interest in this partner search tool, will enable other potential applicants to contact you and invite you to join an applicant consortium.

In addition, you can browse or search the list of contacts in order to find organisations

[www.imi.europa.eu/content/partner-search](http://www.imi.europa.eu/content/partner-search)

[www.imi-partnering.eu](http://www.imi-partnering.eu)



INNOVATIVE MEDICINES INITIATIVE



Home

Call 2009

Partner search

Documents

Links

Contact

Imprint and Privacy

Register here

## Partner Search

Are you preparing a proposal for the next IMI Call 2009 or are you looking for a consortium preparing an application for the 2nd IMI Call? The partner search can help you to find suitable cooperation partners for the next IMI Call 2009. Please note that the topics listed here are draft topics which can change in the official Call Documents. The official Call Documents will be published with the Call on the [official IMI-Website](#). If you want to use the matchmaking function or search the whole list of participants of the IMI-Partnering Platform, please register [here](#).

Role in the consortium

- ☐ Coordinator
- ☐ Partner

Type of organisation

- ☐ Industry
- ☐ SME
- ☐ Research organisation
- ☐ University
- ☐ Patient organisation
- ☐ Regulatory authority
- ☐ Other


Keywords

Draft IMI Topics 2009

- ☐ Efficacy pillar: Oncology
  - ☐ Imaging biomarkers for anticancer drug development
  - ☐ New tools for target validation to improve drug efficacy
  - ☐ Molecular biomarkers
- ☐ Efficacy pillar: Infectious diseases
  - ☐ Identification and development of rapid point care diagnostic tests
- ☐ Knowledge management pillar
  - ☐ Drug/disease modelling: library & framework
  - ☐ Open pharmacological space
  - ☐ Electronic Health Records
- ☐ Efficacy pillar: Inflammation
  - ☐ Understanding aberrant adaptive immunity
  - ☐ Translational research in chronic immune-

# Partner Search Tools & Data bases HealthCompetence

[www.healthcompetence.eu](http://www.healthcompetence.eu)



## Welcome to HealthCompetence

This website includes all projects related to life science and health supported by the European Commission since 2004. It gives visibility to organisations and scientists involved in these projects and, together with interactive search devices, facilitates the identification of potential collaboration partners and the set up of partnerships between academia and industry in health research.

HealthCompetence will also progressively give access to the research results in terms of technology offers, patents and publications.



### Simple Search

Search



### Project Search

find Projects by research field, country and more

Go >>



### Person Search

find Organisations and Persons

Go >>



### Generate your report

use a set of reports to answer your questions on research funded by the European Commission

Go >>



### Upcoming Events

- Info sobre los IP de todos los socios de proyectos financiados en FP6 + FP7 en el ámbito de la salud
- Búsqueda por palabras clave



**AVEDAS**  
Innovation Management



**InsermTransfert**

Coordinated by AVEDAS in collaboration with EFB and InsermTransfert.  
Financed and supported by European Commission - Directorate - General for Research and Innovation



# Partner Search Tools & Data bases- FIT for Health 2.0

[www.fitforhealth.eu](http://www.fitforhealth.eu)



[Home](#)

[Partner Search](#)

[Fit for Health](#) ▾

[News](#)

[Events](#)

[Downloads](#)

[Contact](#) ▾



What are you looking for ?

Bring your research results to the market


Get prepared for Horizon 2020

Join knowledge transfer community



# NCP = facilitator

[http://ec.europa.eu/research/participants/portal/desktop/en/support/national\\_contact\\_points.html](http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.html)



NCPs SALUD

Carolina Carrasco (CDTI) - [carolina.carrasco@cdti.es](mailto:carolina.carrasco@cdti.es)  
Juan Riese (ISCI) - [jriese@eu-isciii.es](mailto:jriese@eu-isciii.es)

# Apoyo CDTI en todas las fases ► NCPs

**¡NO EXCLUSIVO!**

- Oficinas apoyo entidad/local/regional
- Apoyo aspectos concretos EU: socios, IPRs, etc.





# Apoyo CDTI en todas las fases (ii)



- **APCs:** ayuda a la preparación de propuestas comunitarias (empresas) <http://bit.ly/1i2DsHv>
- **Programa de Especialización de Gestores:** estancias de gestores en nuestra oficina SOST – Programa formación + plan de trabajo en Bruselas <http://bit.ly/1iuOHHQ>
- **Oficinas apoyo:** contratación de servicios a entidades especializadas en el apoyo a empresas para su participación en el Horizonte 2020 <http://bit.ly/1g1vzOn>
- **Red PIDi:** Servicio de Información y Asesoramiento Telemático de la Red de Puntos de Información sobre Actividades de Investigación, Desarrollo e Innovación (PI+D+i) → nodo especializado en programas internacionales para la financiación de proyectos de I+D. <http://bit.ly/1gh3w1B>

# ¿Donde hay información?

## Horizonte 2020

[http://ec.europa.eu/research/horizon2020/index\\_en.cfm](http://ec.europa.eu/research/horizon2020/index_en.cfm)



[http://ec.europa.eu/research/horizon2020/index\\_en.cfm](http://ec.europa.eu/research/horizon2020/index_en.cfm)



@EU\_H2020




@EsHorizonte2020

[www.eshorizonte2020.es](http://www.eshorizonte2020.es)

## Web HORIZONTE 2020 ESPAÑA

<http://www.eshorizonte2020.es/>









### **CONTACTO:**

Marta Gómez Quintanilla

Spanish Representative - HEALTH

Spanish Representative - IMI

Spanish MB Member - JPND

☎ 34 91 581 55 62 / 00

[marta.gomez\[at\]cdti.es](mailto:marta.gomez[at]cdti.es) - [www.cdti.es](http://www.cdti.es)